MGS, a global healthcare Contract Development and Manufacturing Organisation, has announced the acquisition of Knudsen Plast A/S, a premier Denmark-based injection moulder with more than 40 years of dedicated healthcare manufacturing experience.
MGS, a healthcare contract development and manufacturing organisation (CDMO), has introduced its newest manufacturing facility in Richfield, Wisconsin.
The BCMPA believes that this year’s Contract Pack & Fulfilment Show firmly underlined the strength of outsourcing specialists and the vital role they play in the packaging supply chain.
Sirio Pharma (Sirio), a global nutraceutical CDMO, has collaborated with ingredient provider OmniActive Health Technologies (OmniActive) to launch a first-in-market soft chew lutein supplement.
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, has announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica.
INTERPHEX WEEK TOKYO will take place from 20-22nd May at Makuhari Messe, bringing together a range of products and services related to pharmaceuticals and regenerative medicine.
Jubilant Biosys, a wholly owned subsidiary of Jubilant Pharmova, and a CRDMO operating from five sites across India and Europe, announced the opening of a new discovery and preclinical facility at Noida, doubling its overall chemistry capacity.
Codexis part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organisation (CRDMO), has announced they have entered into an agreement under which Axolabs will evaluate Codexis’ ECO Synthesis Manufacturing Platform.
The BCMPA, the Association for Contract Manufacturing, Packing, Fulfilment and Logistics, has seen another year of growth with new members, solid partnerships and consistent presence at industry events over the last 12 months.
SteriPack, a global contract design and manufacturing organisation (CDMO) for the pharmaceutical and medical device industries, has announced its trading name change to Ensera, signalling a strategic shift in its identity and service offering.
At CPHI Frankfurt, we sat down with Peter Bains, MD & CEO of Syngene International, to discuss the company’s recent investments in peptides and antibody–drug conjugates (ADCs) and the broader evolution of integrated development in biologics.
